Development of a population pharmacokinetic model to describe olmesartan medoxomil/hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chae, Jung-Woo | - |
dc.contributor.author | Baek, In-hwan | - |
dc.contributor.author | Seo, Jeong-won | - |
dc.contributor.author | Jung, Sang-hoon | - |
dc.contributor.author | Back, Hyun-moon | - |
dc.contributor.author | Song, Byung-jeong | - |
dc.contributor.author | Lee, Byung-yo | - |
dc.contributor.author | Yun, Hwi-yeol | - |
dc.contributor.author | Kang, Wonku | - |
dc.contributor.author | Kwon, Kwang-il | - |
dc.date.available | 2019-03-08T21:38:56Z | - |
dc.date.issued | 2014-08 | - |
dc.identifier.issn | 0946-1965 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/11996 | - |
dc.description.abstract | Aim: The objective of the present study was to develop population pharmacokinetic models for olmesartan medoxomil and hydrochlorothiazide and to investigate the influence of demographic factors on these population pharmacokinetics. Methods: Plasma concentrations of olmesartan medoxomil and hydrochlorothiazide were measured in 41 healthy volunteers enrolled in our bioequivalence study by LC-MS/MS following oral administration of an olmesartan medoxomil/hydrochlorothiazide (20/12.5 mg) fixed-dose combination tablet. This data and covariates were subjected to nonlinear mixed-effect modeling analysis using the NONMEM software. Evaluation featured a visual predicted check and bootstrapping. Results: The distributions of olmesartan medoxomil and hydrochlorothiazide were best fitted using a two-compartment model with no lag time and first-order elimination. When analyzing hydrochlorothiazide kinetics, we found that TCHO and CL/F were correlated, while HB and K-a influenced olmesartan medoxomil modeling. All evaluations indicated that the pharmacokinetic profiles of olmesartan medoxomil and hydrochlorothiazide were adequately described using our PPK model. Conclusions: This study indicates that demographic factors influence the inter-individual variability in the disposition of the combination drug, and it might be more useful to apply it to the PK of olmesartan medoxomil/hydrochlorothiazide (20/12.5 mg) FDC tablets administered to patients with hypertension. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | DUSTRI-VERLAG DR KARL FEISTLE | - |
dc.title | Development of a population pharmacokinetic model to describe olmesartan medoxomil/hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects | - |
dc.type | Article | - |
dc.identifier.doi | 10.5414/CP202046 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, v.52, no.8, pp 676 - 683 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000340815500006 | - |
dc.identifier.scopusid | 2-s2.0-84905815232 | - |
dc.citation.endPage | 683 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 676 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.volume | 52 | - |
dc.type.docType | Article | - |
dc.publisher.location | 독일 | - |
dc.subject.keywordAuthor | olmesartan medoxomil | - |
dc.subject.keywordAuthor | hydrochlorothiazide | - |
dc.subject.keywordAuthor | combination drug | - |
dc.subject.keywordAuthor | nonlinear mixed effect modeling | - |
dc.subject.keywordAuthor | population pharmacokinetic | - |
dc.subject.keywordPlus | TO-MODERATE HYPERTENSION | - |
dc.subject.keywordPlus | PLACEBO-CONTROLLED TRIAL | - |
dc.subject.keywordPlus | COMBINATION THERAPY | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | HUMAN PLASMA | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | HYDROCHLOROTHIAZIDE | - |
dc.subject.keywordPlus | MEDOXOMIL | - |
dc.subject.keywordPlus | LOSARTAN | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.